Significant Increase in Salivary Substance P Level After a Single Oral Dose of Cevimeline in Humans

Overview

Journal Int J Pept

Date 2013 Apr 17

PMID 23589717

Citations 1

Authors

Yosuke Suzuki

Hiroki Itoh

Kohei Amada

Ryota Yamamura

Yuhki Sato

Masaharu Takeyama

Affiliations

Soon will be listed here.

Abstract

Cevimeline is a novel muscarinic acetylcholine receptor agonist currently being developed as a therapeutic agent for xerostomia. We examined the effects of cevimeline on salivary and plasma levels of substance-P- (SP-), calcitonin-gene-related-peptide- (CGRP-), and vasoactive-intestinal-polypeptide- (VIP-) like immunoreactive substances (ISs) in humans. An open-labeled crossover study was conducted on seven healthy volunteers. Saliva volume was measured, and saliva and venous blood samples were collected before and 30-240 min after a single oral dose of cevimeline or placebo. Salivary and plasma levels of SP-, CGRP-, and VIP-IS were measured using a highly sensitive enzyme immunoassay. A single oral dose of cevimeline resulted in significant increases in salivary but not plasma SP-IS level compared to placebo. Cevimeline administration did not alter the salivary or plasma levels of CGRP-IS or VIP-IS compared to placebo. Significant increases in salivary volume were observed after cevimeline administration compared to placebo. A significant correlation was observed between the total release of SP-IS and that of salivary volume. These findings suggest an association of SP with the enhancement of salivary secretion by cevimeline.

Citing Articles

Toan N, Ahn S Int J Mol Sci. 2021; 22(11).

PMID: 34072470 PMC: 8198609. DOI: 10.3390/ijms22115835.

References

Ekstrom J, Mansson B, Tobin G . Vasoactive intestinal peptide evoked secretion of fluid and protein from rat salivary glands and the development of supersensitivity. Acta Physiol Scand. 1983; 119(2):169-75. DOI: 10.1111/j.1748-1716.1983.tb07322.x. View

Bobyock E, CHERNICK W . Vasoactive intestinal peptide interacts with alpha-adrenergic-, cholinergic-, and substance-P-mediated responses in rat parotid and submandibular glands. J Dent Res. 1989; 68(11):1489-94. DOI: 10.1177/00220345890680110401. View

Takeyama M, Mori K, Takayama F, Kondo K, Kitagawa K, Fujii N . Enzyme immunoassay of a substance P-like immunoreactive substance in human plasma and saliva. Chem Pharm Bull (Tokyo). 1990; 38(12):3494-6. DOI: 10.1248/cpb.38.3494. View

Nagano T, Takeyama M . Enhancement of salivary secretion and neuropeptide (substance P, alpha-calcitonin gene-related peptide) levels in saliva by chronic anethole trithione treatment. J Pharm Pharmacol. 2002; 53(12):1697-702. DOI: 10.1211/0022357011778098. View

Lindh B, Hokfelt T . Structural and functional aspects of acetylcholine peptide coexistence in the autonomic nervous system. Prog Brain Res. 1990; 84:175-91. DOI: 10.1016/s0079-6123(08)60902-4. View

Ekstrom J . Autonomic control of salivary secretion. Proc Finn Dent Soc. 1989; 85(4-5):323-31; discussion 361-3. View

Kohler P, Winter M . A quantitative test for xerostomia. The Saxon test, an oral equivalent of the Schirmer test. Arthritis Rheum. 1985; 28(10):1128-32. DOI: 10.1002/art.1780281008. View

Pikula D, HARRIS E, Desiderio D, Fridland G, Lovelace J . Methionine enkephalin-like, substance P-like, and beta-endorphin-like immunoreactivity in human parotid saliva. Arch Oral Biol. 1992; 37(9):705-9. DOI: 10.1016/0003-9969(92)90076-k. View

Fife R, Chase W, Dore R, Wiesenhutter C, Lockhart P, Tindall E . Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch Intern Med. 2002; 162(11):1293-300. DOI: 10.1001/archinte.162.11.1293. View

10.

Ekstrom J, Ekman R, Hakanson R, Sjogren S, Sundler F . Calcitonin gene-related peptide in rat salivary glands: neuronal localization, depletion upon nerve stimulation, and effects on salivation in relation to substance P. Neuroscience. 1988; 26(3):933-49. DOI: 10.1016/0306-4522(88)90110-8. View

11.

Ekstrom J, Mansson B, Tobin G . Non-adrenergic, non-cholinergic parasympathetic secretion in the rat submaxillary and sublingual glands. Pharmacol Toxicol. 1987; 60(4):284-7. DOI: 10.1111/j.1600-0773.1987.tb01753.x. View

12.

Larsson O, Lundberg J, Fredholm B, Anggard A . Effects of VIP, PHM and substance P on blood vessels and secretory elements of the human submandibular gland. Regul Pept. 1986; 13(3-4):319-26. DOI: 10.1016/0167-0115(86)90049-2. View

13.

Navazesh M, Christensen C . A comparison of whole mouth resting and stimulated salivary measurement procedures. J Dent Res. 1982; 61(10):1158-62. DOI: 10.1177/00220345820610100901. View

14.

Naito T, Itoh H, Takeyama M . Effects of Hange-koboku-to (Banxia-houpo-tang) on neuropeptide levels in human plasma and saliva. Biol Pharm Bull. 2003; 26(11):1609-13. DOI: 10.1248/bpb.26.1609. View

15.

Takeyama M, Wakayama K, Takayama F, Kondo K, Fujii N, Yajima H . Micro-enzyme immunoassay of vasoactive intestinal polypeptide (VIP)-like immunoreactive substance in bovine milk. Chem Pharm Bull (Tokyo). 1990; 38(4):960-2. DOI: 10.1248/cpb.38.960. View

16.

Hauser-Kronberger C, Saria A, Hacker G . [Peptidergic innervation of human salivary glands (parotid gland and submandibular gland)]. HNO. 1992; 40(11):429-36. View

17.

BLOCH K, BUCHANAN W, WOHL M, Bunim J . Sjögren's syndrome. A clinical, pathological, and serological study of sixty-two cases. 1965. Medicine (Baltimore). 1992; 71(6):386-401; discussion 401-3. View

18.

EMMELIN N . Nerve interactions in salivary glands. J Dent Res. 1987; 66(2):509-17. DOI: 10.1177/00220345870660022101. View

19.

Dawidson I, Blom M, Lundeberg T, Theodorsson E, Angmar-Mansson B . Neuropeptides in the saliva of healthy subjects. Life Sci. 1997; 60(4-5):269-78. DOI: 10.1016/s0024-3205(96)00627-3. View

20.

Iwabuchi Y, Masuhara T . Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjörgen's syndrome. Gen Pharmacol. 1994; 25(1):123-9. DOI: 10.1016/0306-3623(94)90021-3. View